Delving into the Latest Updates on Polyclonal antibody stimulator(Aphton Corp.) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Conjugated vaccine

Synonyms

Anti-gastrin 17 immunogen, Antigastrin 17, Gastrimmune

+ [9]

Target

GAST

Action

inhibitors, stimulants

Mechanism

Gastrin-17 inhibitors(Gastrin 17 inhibitors), Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Pancreatic CancerStomach Cancer

Inactive Indication

Adenocarcinoma of large intestineEsophageal CarcinomaGastroesophageal Reflux+ [5]

Originator Organization

Aphton Corp.

Active Organization

Aphton Corp.

Inactive Organization

Cancer Advances, Inc.

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

Start Date01 Jul 2001

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

NCT02118077

/ CompletedPhase 3

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

Start Date01 Apr 2001

Sponsor / Collaborator

Cancer Advances, Inc.

NCT02118064

/ CompletedPhase 2

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

Start Date01 Mar 2001

Sponsor / Collaborator

Cancer Advances, Inc.

100 Clinical Results associated with Polyclonal antibody stimulator(Aphton Corp.)

Login to view more data

100 Translational Medicine associated with Polyclonal antibody stimulator(Aphton Corp.)

Login to view more data

100 Patents (Medical) associated with Polyclonal antibody stimulator(Aphton Corp.)

Login to view more data

2,720

Literatures (Medical) associated with Polyclonal antibody stimulator(Aphton Corp.)

01 Oct 2025·Journal of Environmental Sciences

Developmental exposure to echimidine induces locomotor hyperactivity in zebrafish larvae via inhibiting acetylcholinesterase activity

Article

Author: Ren, Yingyi ; Luo, Zhiqiang ; He, Chengyong ; Lin, Tingting ; Chen, Siyu ; Yang, Jian ; Liang, Junyu ; Zuo, Zhenghong

Pyrrolizidine alkaloids (PAs) are natural toxins generated as secondary metabolites in plants, predominantly consisting of unsaturated PAs with diverse toxicities, such as hepatotoxicity. Echimidine, a prominent PA, is believed to exert various toxicological effects, including survival inhibition and induction of apoptosis of hepatocytes. However, the effects of echimidine on development remain unclear. We selected three concentrations of 0.02, 0.2, and 2 mg/L to investigate the developmental toxicity of echimidine on zebrafish embryos. After a 7-day exposure, we observed hyperactivity and anxiety-like behavior in zebrafish larvae. Furthermore, we found that echimidine exposure significantly promoted embryonic motor neurodevelopment in genetically modified zebrafish. Next, we detected that echimidine exposure significantly increased the content of the excitatory neurotransmitter acetylcholine (ACh), accompanied by a significant decrease in acetylcholinesterase (AChE) activity. Conversely, echimidine led to a significant reduction in the content of the sedative neurotransmitter γ-aminobutyric acid (GABA), accompanied by abnormal gene expression of enzymes related to GABA synthesis. Moreover, we elucidated the strong direct binding of echimidine to zebrafish and human AChE protein through molecular docking. In summary, our study found that echimidine induced ACh accumulation possibly by inhibiting AChE activity, leading to motor neurodevelopmental abnormalities and hyperactivity in zebrafish larvae. This work provides important scientific knowledge on the effects and mechanisms of PAs on neural development, which is helpful for controlling the risk of PAs in food and protecting public health.

01 Sep 2025·FOOD CHEMISTRY

Magnetic graphene oxide nanocomposite materials for magnetic dispersive solid-phase extraction and determination of pyrrolizidine alkaloids in tea beverages

Article

Author: Li, Shiqi ; Yi, Yuexing ; Huang, Xuchen ; Ma, Guicen ; Chen, Hongping ; Li, Zuguang ; Lu, Yuting

Pyrrolizidine alkaloids (PAs) and their N-oxides (PANOs) are plant-derived toxins, and tea beverages represent one of the most important exposure pathways of PAs/PANOs for human being. Therefore, establishing a method for the sensitive determination of PAs/PANOs is of great significance. In this study, magnetic graphene oxide (MGO) nanocomposite materials were used as an adsorbent in magnetic dispersive solid-phase extraction (d-MSPE) for quantifying PAs/PANOs in tea beverages. MGO exhibited high adsorption efficiency of PAs/PANOs from 83 % to 99 %, with rapid adsorption occurring within 20 min and desorption taking only 6 min. Under optimized conditions, the method showed excellent linearity (1-500 μg/L), low detection limits (0.01-0.6 μg/L), and good precision (RSD < 9.4 %). These results demonstrate the d-MSPE is a simple, efficient, and rapid method for the sample pretreatment and determination of PAs/PANOs in tea beverages.

01 Aug 2025·FOOD CHEMISTRY

Comprehensive review of pyrrolizidine alkaloids in bee products: Occurrence, extraction, and analytical methods

Review

Author: Gonzaga, Luciano Valdemiro ; Costa, Ana Carolina Oliveira ; Silva, Bibiana ; Brugnerotto, Patricia

Pyrrolizidine alkaloids (PAs) and their N-oxides (PANOs) are hepatotoxic secondary metabolites present in certain plant genera, raising health concerns due to their inevitable occurrence in bee products like honey, pollen, royal jelly, and propolis. The European Commission has set a 500 μg kg^-1 limit for PAs/PANOs in pollen-based supplements to ensure safety, emphasizing the need for sensitive analytical methods. This review, based on studies published between 2019 and 2024, identifies 51 compounds in bee products, including 32 PAs and 19 PANOs, with lycopsamine, senecionine, echimidine, intermedine, and retrorsine being the most studied. Solvent extraction, often combined with SPE or QuEChERS, is the most used preparation method, while liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is preferred for detection. Few studies assessed the risk of PAs consumption. These findings support regulatory monitoring of bee product safety and highlight the need for refining detection methods and establishing standardized limits and monitoring for PAs/PANOs.

1

News (Medical) associated with Polyclonal antibody stimulator(Aphton Corp.)

28 Feb 2023

·www.biospace.com

Cancer Advances, Inc. Announces Issuance of New U.S. Patent - February 28, 2023

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers. The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination. “After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances. The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience. About Polyclonal Antibody Stimulator (PAS) Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program. Contact Cancer Advances, Inc. E-mail: jwingen@canceradvances.com

VaccineImmunotherapy

100 Deals associated with Polyclonal antibody stimulator(Aphton Corp.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB04914

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Cancer	Phase 3	United States	Cancer Advances, Inc.	19 Jan 2009
Pancreatic adenocarcinoma	Phase 3	-	Cancer Advances, Inc.	14 Aug 2000
Pancreatic Cancer	Phase 3	-	Aphton Corp.	-
Gastroesophageal Reflux	Phase 2	United States	Cancer Advances, Inc.	20 Jan 2009
Esophageal Carcinoma	Phase 2	-	Cancer Advances, Inc.	01 Aug 2000
Malignant neoplasm of gastro-oesophageal junction	Phase 2	-	Cancer Advances, Inc.	01 Aug 2000
Jaundice	Phase 2	-	Cancer Advances, Inc.	01 Aug 1999
stomach adenocarcinoma	Phase 2	-	Cancer Advances, Inc.	01 Sep 1998
Adenocarcinoma of large intestine	Phase 2	United Kingdom	Cancer Advances, Inc.	01 Oct 1993
Metastatic Colorectal Carcinoma	Phase 2	United Kingdom	Cancer Advances, Inc.	01 Oct 1993

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2006	Phase 3	Pancreatic Cancer	-	Gemcitabine + G17DT	gvdpopqxga(ebqorubbpe) = rfbeiespzt qaujkbqksb (txuwjsxhao )	-	20 Jun 2006
				Gemcitabine alone (placebo)	gvdpopqxga(ebqorubbpe) = gkzobxfugd qaujkbqksb (txuwjsxhao )
ASCO2004	Not Applicable	Pancreatic carcinoma non-resectable	154	G17DT	pqiglcaoqv(dalpkxipct) = keqbhwsvoa lzkogltdov (cmazspmdae )	Positive	15 Jul 2004
				Placebo	pqiglcaoqv(dalpkxipct) = rgqywvevzm lzkogltdov (cmazspmdae )